GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

XtalPi has accrued a number of Big Pharma partners over the years, including Eli Lilly, which struck a $250 million deal in 2023 to use XtalPi’s tech to identify potential drug candidates that Lilly ...

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...

Novo Nordisk A/S and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their ...

Developed by Eli Lilly in Indianapolis, Indiana, mazdutide is manufactured by Innovent Biologics in Suzhou, China, under an exclusive licence. Other trials are testing whether the drug can treat sleep ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

A U.K. health agency said the Alzheimer's drugs Kisunla and Leqembi are not cost-effective, meaning they won't be offered through the NHS.

Internal documents revealed Takeda and Lilly knew about the bladder cancer risk as early as 1999. After the FDA mandated a bladder cancer warning for Actos in 2011, drug sales dropped by 80% ...

Eli Lilly (NYSE: LLY) has been one of the hottest healthcare stocks to own in recent years, thanks in large part to the success of its incredibly successful GLP-1 agonist drugs, which help ...

Eli Lilly offered a 115% premium for Verve, signaling a major vote of confidence in gene editing platforms. HC Wainwright and William Blair downgraded Verve after the deal. Market-moving news hits ...

Boston Globe via Getty Images Eli Lilly’s $1.3 billion acquisition of Verve Therapeutics represents a strategic move into cardiovascular genetic medicine.